Didem Şener Dede

Didem Şener Dede

Auto-generated profile, based on publicly available information

Didem Şener Dede

Department of Medical Oncology, Ankara Bilkent City Hospital, 06800 Ankara, Turkey

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 January 2020 in Current Medical Research and Opinion
Verified
Journal Article
Closed access
MHMutlu Hizal
Mutlu Hizal
MSMehmet Ali Nahit SENDUR
Mehmet Ali Nahit SENDUR
BBBurak Bilgin
Burak Bilgin
MAMuhammed Bulent Akinci
Muhammed Bulent Akinci
DDDidem Sener Dede
Didem Sener Dede
BYBulent Yalcin
Bulent Yalcin
Background: Renal cell carcinoma (RCC) is the most common type of renal malignancy with 87% frequency. As a global health problem, kidney cancer is responsible for 2.2% of new cancer cases. One of the highly effective mechanisms that renal cancer cells avoid in the immune system is PD-1 and PD-L1 interaction. Scope: Literature search is made from PubMed, Medline, and ASCO and ESMO Annual Meeting abstracts using the following search keywords: “nivolumab,” “pembrolizumab,” “atezolizumab,” “avelumab,” “durvalumab,” and “renal cell cancer.” The last search was on November 1, 2019. Findings: The combination of nivolumab and ipilimumab have better survival results than sunitinib for intermediate and poor risk patients but not for favorable risk groups. In 2019, two combination regimens with pembrolizumab plus axitinib and avelumab plus axitinib demonstrated efficacy over sunitinib for every risk group. The overall survival data of these trials are still immature. Conclusions: Advanced RCC has high morbidity and mortality with an increasing prevalence. Following tyrosine kinase inhibitors, checkpoint inhibitors have a great influence on treatment of advanced RCC, especially the combination of these two strategies. In 2019 these combined strategies demonstrated 5% complete remission with up to 60% objective response rate. While not immediately, but perhaps in the near future, advanced RCC will become a manageable chronic disease, even if a cure is not possible.

Verified
Journal Article
Open access
PDF file
SÖSeda Er Özilhan
Seda Er Özilhan
SESafa Can Efil
Safa Can Efil
DÇDoğukan Çanakçı
Doğukan Çanakçı
YAYetkin Ağaçkıran
Yetkin Ağaçkıran
DDDidem Şener Dede
Didem Şener Dede
HDHayriye Tatlı Dogan
Hayriye Tatlı Dogan
Background: Lung cancer remains the leading cause of cancer-related deaths worldwide, with non-small cell lung carcinomas (NSCLCs) comprising the majority of cases. Among the common driver mutations, KRAS plays a critical role in guiding treatment strategies. This study evaluates the expression of programmed death-ligand 1 (PD-L1) and hypoxia-inducible factor 1-alpha (HIF-1α) in KRAS-mutant NSCLCs and investigates their associations with clinicopathological findings. Methods: A total of 85 cases with KRAS mutations were analyzed. Immunohistochemical staining for HIF-1α and PD-L1 was performed, and their relationships with mutation status and prognostic variables were assessed. Results: A significant correlation was identified between HIF-1α expression and PD-L1 expression in tumor cells. While the KRAS G12C mutation was not significantly associated with HIF-1α expression in tumor cells, it demonstrated a notable relationship with HIF-1α expression in the tumor microenvironment and PD-L1 expression. However, PD-L1 and HIF-1α expression did not significantly influence overall survival outcomes. Conclusions: Expression of PD-L1 was positively correlated with HIF-1α, which may provide evidence for a novel therapy targeting PD-L1 and HIF-1α in NSCLC. Further comprehensive studies are warranted to elucidate the prognostic implications of tumor–microenvironment and mutation interactions.

1 August 2019 in Journal of Oncological Sciences
Verified
Journal Article
Open access
BBBurak Bilgin
Burak Bilgin
MSMehmet Ali Nahit SENDUR
Mehmet Ali Nahit SENDUR
MHMutlu Hizal
Mutlu Hizal
SKSümeyye Ulutas Kandil
Sümeyye Ulutas Kandil
SYSamet Yaman
Samet Yaman
BYBulent Yalcin
Bulent Yalcin

31 December 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
FCFurkan Ceylan
Furkan Ceylan
MMMırmehdi Mehtıyev
Mırmehdi Mehtıyev
DDDidem Şener Dede
Didem Şener Dede
SESafa Can Efil
Safa Can Efil
ATAteş Kutay TENEKECİ
Ateş Kutay TENEKECİ
BYBulent Yalcin
Bulent Yalcin
Background: Although CDK4/6 inhibitors combined with endocrine therapies have improved outcomes in HR+ HER2-negative metastatic breast cancer, predictive biomarkers for treatment response and adverse effects remain limited. This study assessed the prognostic and predictive value of large unstained cells (LUC), a subset of white blood cells that may reflect immune status or treatment response. Methods: A retrospective analysis of 210 patients with HR+ HER2-negative metastatic breast cancer treated with CDK 4/6 inhibitors between 2021 and 2024 was conducted. Clinical data, including demographics, tumor characteristics, and treatment regimens, were analyzed. Based on LUC levels, progression-free survival (PFS), overall survival (OS), and adverse events were evaluated. Results: The cohort had a median age of 57, of which 78% were postmenopausal. Common metastatic sites included bone (67%) and liver (24%). At a median follow-up of 18.5 months, the PFS and OS rates were 65% and 83%. Patients with low LUC levels had significantly shorter PFS (OR: 1.91; p = 0.014) and OS (OR: 2.39; p = 0.012), while high LUC levels correlated with a lower incidence of grade 3 neutropenia (OR: 0.49; p = 0.017). Liver metastasis and prior treatments were also linked to shorter survival. Conclusions: LUC levels emerge as a promising biomarker for predicting survival outcomes and the risk of neutropenia in HR+ HER2-negative metastatic breast cancer patients treated with CDK 4/6 inhibitors and endocrine therapy, showing their potential to guide personalized treatment approaches.

31 August 2021 in Tıp Eğitimi Dünyası
Verified
Journal Article
Closed access
AÖAyhan Özhasenekler
Ayhan Özhasenekler
BDBasri Furkan Dağcioğlu
Basri Furkan Dağcioğlu
DŞDidem Şener
Didem Şener
ATAhmet Çevik Tufan
Ahmet Çevik Tufan
REReyhan Ersoy
Reyhan Ersoy
Amaç: 2019-2020 akademik yılı bahar yarıyılı COVID-19 pandemi döneminde Ankara Yıldırım Beyazıt Üniversitesi (AYBÜ) Tıp Fakültesi Öğretim Üyelerinin uzaktan eğitim yöntemleri hakkındaki tecrübelerini paylaşmak ve konu hakkındaki görüşlerini değerlendirmektir.Yöntem: AYBÜ Tıp Fakültesinde görev yapan 282 öğretim üyesine çevrimiçi anket uygulanması yöntemiyle veri toplandı. Kesitsel çalışma olarak planlandı. Hazırlanan anket iki bölümden oluşmaktaydı. İlk bölümde katılımcıların demografik verileri, ikinci bölümde önümüzdeki süreçte uzaktan eğitim yöntemlerinin Tıp Fakültesi eğitiminde uygulanmasına yönelik değerlendirme sorularına yer verildi. Sorular üçlü likert tipinde hazırlandı ve sorulara verilen cevaplar ‘1-Evet, 2-Karasızım, 3-Hayır’ şeklinde derecelendirildi. Sayısal değerler % (n) olarak ifade edildi.Bulgular: Çalışmaya 282 öğretim üyesinin 198’i (%70,2) katıldı. Katılımcıların; %50,5’i (n:100) kadın, yaş ortalaması en çok 41-50 yıl (%44,9 n:89), %48’i (n:95) Profesör, %61,1’i (n:121) Dahili Tıp Bilimlerinden ve %46,5’i (n:92) 5-10 yıl arası öğretim üyesi olarak çalışmaktaydı. Katılımcıların %92,9’u (n:184) daha önceden uzaktan eğitim ile ilgili oryantasyon eğitimi almadıklarını ifade etmişlerdi. Katılımcılar Tıp Fakültesi akademik programında uzaktan eğitim yöntemlerinin sağlayacağı olumlu yönleri; en çok zamanı iyi kullanma, pratik derslere daha çok zaman ayırma, öğrencilerin daha küçük gruplarla pratik eğitimlere katılması şeklinde görüş belirtmişlerdir. Olumsuz yönleri; birebir ve yüz yüze eğitimdeki gibi karşılıklı etkileşimlerin olmaması, rol model ve koçluk tarzında eğitim şansının olmaması, geri bildirim eksikliği, kurum aidiyetinin azalması, öğrencilerin çevre ve arkadaşları ile etkileşiminin azalması şeklinde görüş belirtmişlerdir.Sonuç: COVID-19 pandemisi hayatın birçok alanında olduğu gibi Tıp Eğitimini de olumsuz etkilemiştir. Bu dönemden öğretim üyelerimiz, öğrencilerimiz ve kurumlarımız adına çıkarım yaparak yeni süreç hakkında kendimizi geliştirmeyi ve eğitim programlarımızı karşılaşılabilecek her türlü olağanüstü duruma hazır hale getirmemiz gerektiğini düşünmekteyiz.

27 January 2025 in Cancers
Verified
Journal Article
Open access
PDF file
FCFurkan Ceylan
Furkan Ceylan
MMMırmehdi Mehtıyev
Mırmehdi Mehtıyev
BBBurak Bilgin
Burak Bilgin
ATAteş Kutay TENEKECİ
Ateş Kutay TENEKECİ
BYBulent Yalcin
Bulent Yalcin
ŞYŞebnem Yücel
Şebnem Yücel
Purpose: CDK4/6 inhibitors require meticulous monitoring due to their potential to cause hematological toxicities and hepatotoxicity. This study evaluates the safety of combining CDK4/6 inhibitors with palliative radiotherapy in patients with metastatic hormone receptor-positive and HER2-negative breast cancer. Patients and Methods: This study included 188 patients treated with CDK4/6 inhibitors between January 2021 and June 2024. Data on patient demographics, tumor characteristics, and treatment interventions were extracted from medical records. The primary focus was on the incidence of grade ≥ 3 hematologic toxicities and hepatotoxicity, assessed according to CTCAE 5.0 criteria, in those receiving concurrent palliative radiotherapy. Results: With a median follow-up of 18.5 months, the 18-month PFS and OS rates were 67% and 85%, respectively. The median age was 57.5 years, and 79% of patients were post-menopausal. Bone and liver metastases were present in 66% and 23% of patients, respectively. Concurrent palliative radiotherapy was administered in 25% of the cohort. The incidence of grade ≥ 3 hematologic toxicity was comparable between those who received radiotherapy and those who did not. Ribociclib use was associated with lower rates of grade 3 hematologic toxicity (OR: 0.37), neutropenia (OR: 0.41), dose interruptions (OR: 0.30), and dose reductions (OR: 0.37). Pre-menopausal status was linked to fewer dose reductions (OR: 0.17). Rates of treatment interruption, dose reduction, and withdrawal were 55%, 24%, and 2%, respectively. Conclusions: The concurrent use of CDK4/6 inhibitors and palliative radiotherapy does not increase the incidence of hematological adverse events in patients with metastatic breast cancer.